Latest Ratios: P/E Ratio -3.9x · EV/EBITDA N/A · ROE -99.5%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $390M | $223M | $96M | $258M | $286M | $593M | $3.1B | — | — |
| Enterprise Value | $373M | $206M | $102M | $249M | $257M | $563M | $2.9B | — | — |
| P/E Ratio → | -3.85 | — | — | — | — | — | — | — | — |
| P/S Ratio | 32.14 | 18.38 | 13.75 | — | — | — | — | — | — |
| P/B Ratio | 5.57 | 3.25 | 0.73 | 1.09 | 1.46 | 2.07 | 14.74 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 16.94 | 14.55 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.9% | 85.9% | 100.0% | — | — | — | — | — | — |
| Operating Margin | -861.3% | -861.3% | -1995.9% | — | — | — | — | — | — |
| Net Profit Margin | -819.6% | -819.6% | -1816.8% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -99.5% | -99.5% | -69.0% | -56.3% | -48.0% | -44.8% | -69.9% | — | — |
| ROA | -62.8% | -62.8% | -56.1% | -48.9% | -43.9% | -42.3% | -46.4% | -144.1% | -89.5% |
| ROIC | -83.4% | -83.4% | -57.3% | -50.2% | -43.9% | -68.3% | — | — | — |
| ROCE | -87.8% | -87.8% | -68.9% | -58.2% | -51.0% | -45.7% | -51.3% | -181.4% | -107.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.26 | 0.26 | 0.14 | 0.07 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | 0.04 | -0.04 | -0.15 | -0.11 | -1.03 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($35M) exceeds total debt ($18M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.99 | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | 4.18 | 6.37 |
| Quick Ratio | 1.99 | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | 4.18 | 6.37 |
| Cash Ratio | 1.95 | 1.95 | 5.21 | 10.67 | 9.30 | 15.17 | 19.19 | 3.90 | 6.37 |
| Asset Turnover | — | 0.09 | 0.04 | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $77M | $76M | $60M | $47M | $48M | $44M | $32M | $2M |
Critical cash runway deficiency
As reported in financial statements, Prelude's P/S ratio of 28.32 suggests that investors are pricing the company based on speculative future pipeline success rather than current fundamentals, a valuation premium that appears disconnected from the firm's lack of recurring revenue and persistent, high-intensity clinical development cash burn.
The elevated P/S multiple relative to the broader biotech sector indicates that the market is assigning significant optionality to the company's small-molecule discovery engine. However, this valuation appears fragile, as it relies on the assumption of successful clinical readouts that remain unproven and highly susceptible to competitive pressures in the PRMT5 and CDK9 landscapes.
Based on the company's reported figures, ROIC has trended downward from -11.9% in 2024Q1 to -19.8% in 2026Q1, illustrating a consistent decay in the efficiency of invested capital as the firm continues to fund extensive clinical trials without achieving a self-sustaining commercial return on its research investments.
The persistent negative ROIC reflects the structural reality of a clinical-stage firm where capital is consumed by R&D rather than deployed into revenue-generating assets. This trend warrants further investigation into whether the current pipeline prioritization is sufficient to eventually reverse this value-destructive cycle before the cash runway is exhausted.
According to recent SEC filings, the company's current ratio has compressed significantly from 11.64 in 2024Q1 to 2.03 in 2026Q1, signaling a tightening liquidity position as cash reserves are rapidly depleted to support the ongoing, high-cost clinical development of its oncology pipeline against limited incoming milestone payments.
While a current ratio of 2.03 may appear adequate in isolation, it masks the reality of a high-burn business model where cash is the primary lifeline. Investors should monitor the company's ability to maintain this liquidity buffer, as any delay in clinical milestones could necessitate dilutive financing to sustain operations.
As indicated by the provided financial data, the P/S ratio is a fundamentally misapplied metric for Prelude, as it obscures the non-recurring, milestone-driven nature of the company's revenue, which does not represent sustainable commercial demand but rather the accounting recognition of past collaboration agreements and upfront payments.
Analysts should instead focus on the cash-to-burn ratio and the clinical trial enrollment velocity to assess the company's true operational health. Relying on revenue-based valuation multiples for a pre-commercial entity risks overestimating the firm's stability and ignoring the critical risk of future equity dilution required to fund ongoing research.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRLD stock.
Prelude Therapeutics Incorporated's current P/E ratio is -3.9x. This places it at the 50th percentile of its historical range.
Prelude Therapeutics Incorporated's return on equity (ROE) is -99.5%. The historical average is -64.6%.
Based on historical data, Prelude Therapeutics Incorporated is trading at a P/E of -3.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Prelude Therapeutics Incorporated has 85.9% gross margin and -861.3% operating margin.